Prophylaxis and therapy for chikungunya virus infection

Journal of Infectious Diseases

Volumn 200, Issue 4, 2009, Pages 516-523

  Couderc, Thérèse ^a,c   Khandoudi, Nassirah ^e   Grandadam, Marc ^b,f   Visse, Catherine ^e   Gangneux, Nicolas ^a,c   Bagot, Sébastien ^e   Prost, Jean François ^e   Lecuit, Marc ^a,b,c,d  

^a Groupe Microorganismes et Barrières de i'Hôte   (France)

^b INSTITUT PASTEUR   (France)

^c INSERM   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Laboratoire Francais du Fractionnement et des Biotechnologies   (France)

^f SERVICE DE SANTÉ DES ARMÉES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; INTERFERON RECEPTOR; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARBOVIRUS; ARTHRALGIA; ARTICLE; BLOOD DONOR; BLOOD SAMPLING; CHIKUNGUNYA ALPHAVIRUS; CHIKUNGUNYA ALPHAVIRUS INFECTION; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FEVER; HUMAN; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INDIAN OCEAN; MOUSE; MYALGIA; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RASH; THERAPY EFFECT; VIRUS INFECTION; ADULT; ANIMAL; BLOOD; GENETICS; IMMUNOLOGY; MOUSE MUTANT; TIME;

ADULT; ALPHAVIRUS INFECTIONS; ANIMALS; CHIKUNGUNYA VIRUS; HUMANS; IMMUNOGLOBULINS; MICE; MICE, KNOCKOUT; RECEPTORS, INTERFERON; TIME FACTORS; VIRAL VACCINES;

EID: 69149108038     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/600381     Document Type: Article

References (43)

1. Robinson MC. An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-1953.1. Clinical features. Trans R Soc Trop Med Hyg 1955;49:28-32.
2. Enserink M. Infectious diseases: massive outbreak draws fresh attention to little-known virus. Science 2006;311:1085.
3. Bonn D. How did Chikungunya reach the Indian Ocean? Lancet Infect Dis 2006; 6:543.
4. Josseran L, Paquet Q Zehgnoun A, et al. Chikungunya disease outbreak, Reunion Island. Emerg Infect Dis 2006; 12:1994-1995
5. Bessaud M, Peyrefitte CN, Pastorino BA, et al. Chikungunya virus strains, Reunion Island outbreak. Emerg Infect Dis 2006; 12:1604-1606
6. 6. Schuffenecker I, Iteman I, Michault A, et al. Genome microevolution of Chikungunya viruses causing the Indian Ocean outbreak. PLoS Med 2006;3:e263. (Pubitemid 44125992)
7. Pialoux G, Gauzere BA, Jaureguiberry S, Strobel M. Chikungunya, an epidemic arbovirosis. Lancet Infect Dis 2007;7:319-327
8. Ravi V. Re-emergence of Chikungunya virus in India. Indian J Med Microbiol 2006;24:83-84
9. Saxena SK, Singh M, Mishra N, Lakshmi V. Resurgence of Chikungunya virus in India: an emerging threat. Euro Surveill 2006; 11:E060810.2.
10. 10. Mavalankar D, Shastri P, Raman P. Chikungunya epidemic in India: a major public-health disaster. Lancet Infect Dis 2007; 7:306-307 (Pubitemid 46613867)
11. Gratz NG. Emerging and resurging vector-borne diseases. Annu Rev Entomol 1999;44:51-75.
12. 12. Charrel RN, de Lamballerie X, Raoult D. Chikungunya outbreaks-the globalization of vectorborne diseases. N Engl J Med 2007;356:769-771 (Pubitemid 46294608)
13. 13. Rezza G, Nicoletti L, Angelini R, et al. Infection with Chikungunya virus in Italy: an outbreak in a temperate region. Lancet 2007;370:1840-1846 (Pubitemid 350180033)
14. 14. Diallo M, Thonnon J, Traore-Lamizana M, Fontenille D. Vectors of Chikungunya virus in Senegal: current data and transmission cycles. Am J Trop Med Hyg 1999;60:281-286 (Pubitemid 29107118)
15. Borgherini G, Poubeau P, Jossaume A, et al. Persistent arthralgia associated with Chikungunya virus: a study of 88 adult patients on reunion island. Clin Infect Dis 2008; 47:469-475
16. Lemant J, Boisson V, Winer A, et al. Serious acute Chikungunya virus infection requiring intensive care during the Reunion Island outbreak in 2005-2006. Crit Care Med 2008;36:2536-2541
17. Gérardin P, Carbonnier M, Bintner M, et al. Severe neonatal encephalopathy and haemorrhagic fever as a complication of materno-fetal transmission of Chikungunya virus. PLoS Medicine 2008; 5:e60.
18. Lenglet Y, Barau G, Robillard PY, et al. Chikungunya infection in pregnancy: evidence for intrauterine infection in pregnant women and vertical transmission in the parturient: survey of the Reunion Island outbreak [in French], J Gynecol Obstet Biol Reprod (Paris) 2006;35: 578-583
19. 19. Couderc T, Chrétien F, Schilte C, et al. A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathogens 2008; 4:e29. (Pubitemid 351340700)
20. 20. Laurent P, Le Roux K, Grivard P, et al. Development of a sensitive real-time reverse transcriptase PCR assay with an internal control to detect and quantify Chikungunya virus. Clin Chem 2007;53:1408-1414 (Pubitemid 47214396)
21. Dunman PM, Nesin M. Passive immunization as prophylaxis: when and where will this work? Curr Opin Pharmacol 2003; 3:486-496
22. Keller M, Deveikis A, Cu tillar-Garcia M, et al. Pneumococcal and influenza immunization and human immunodeficiency virus load in children. Pediatr Infect Dis J 2000; 19:613-618
23. Dessain SK, Adekar SP, Berry JD. Exploring the native human antibody repertoire to create antiviral therapeutics. Curr Top Microbiol Immunol 2008;317:155-183
24. 24. Shimoni Z, Niven MJ, Pitlick S, Bulvik S. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis 2001; 7:759. (Pubitemid 32845276)
25. 25. Hamdan A, Green P, Mendelson E, Kramer MR, Pitlik S, Weinberger M. Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl Infect Dis 2002;4:160-162 (Pubitemid 35364781)
26. 26. Phillpotts RJ. Immunity to airborne challenge with Venezuelan equine encephalitis virus develops rapidly after immunization with the attenuated vaccine strain TC-83. Vaccine 1999; 17:2429-2435 (Pubitemid 29268366)
27. 27. Stanley J, Cooper SJ, Griffin DE. Monoclonal antibody cure and prophylaxis of lethal Sindbis virus encephalitis in mice. J Virol 1986; 58: 107-115 (Pubitemid 16021965)
28. 28. Pastorino B, Bessaud M, Grandadam M, Murri S, Tolou HJ, Peyrefitte CN. Development of a TaqMan RT-PCR assay without RNA extraction step for the detection and quantification of African Chikungunya viruses. J Virol Methods 2005; 124:65-71. (Pubitemid 40142652)
29. Gardi A. Quality control in the production of an immunoglobulin for intravenous use. Blut 1984;48:337-344
30. Peyrefitte CN, Rousset D, Pastorino BA, et al. Chikungunya virus, Cameroon, 2006. Emerg Infect Dis 2007; 13:768-771
31. 31. Muller U, Steinhoff U, Reis LF, et al. Functional role of type I and type II interferons in antiviral defense. Science 1994;264:1918-1921 (Pubitemid 24245635)
32. Chevillon Q Briant L, Renaud F, Devaux C. The Chikungunya threat: an ecological and evolutionary perspective. Trends Microbiol 2008; 16: 80-88
33. 33. Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA. Phase II safety and immunogenicity study of live Chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 2000; 62:681-685 (Pubitemid 32281485)
34. Myers RM, Carey DE. Concurrent isolation from patient of two arboviruses, Chikungunya and dengue type 2. Science 1967; 157:1307-1308
35. Rabinowitz SG, Adler WH. Host defenses during primary Venezuelan equine encephalomyelitis virus infection in mice. I. Passive transfer of protection with immune serum and immune cells. J Immunol 1973; 110:1345-1353
36. Boere WA, Benaissa-Trouw BJ, Harmsen M, Kraaijeveld CA, Snippe H. Neutralizing and non-neutralizing monoclonal antibodies to the E2 glycoprotein of Semliki Forest virus can protect mice from lethal encephalitis. J Gen Virol 1983;64:1405-1408
37. Engle MJ, Diamond MS. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol 2003;77:12941-12949
38. 38. Ben-Nathan D, Lustig S, Tam G, Robinzon S, Segal S, Rager-Zisman B. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis 2003; 188:5-12. (Pubitemid 36829736)
39. Mathews JH, Roehrig JT, Trent DW Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies. J Virol 1985;55:594-600.
40. 40. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24:44-46 (Pubitemid 40179131)
41. Yeh KM, Chiueh TS, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother 2005;56:919-922
42. 42. Zhang Z, Xie YW, Hong J, et al. Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma. Transfusion 2005;45:1160-1164 (Pubitemid 40935016)
43. 43. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007;357:1450-1451 (Pubitemid 47535608)